A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
← catalyst calendarNCT05999994 · readout ≤ 285 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
105estimated
Sites
72
Countries
Australia, Belgium, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-01-22 | actual | When the study began enrolling |
| Primary completion | May 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Neoplasms
- Child
- Adolescent
Interventions
- Drug: Ramucirumab — also filed as LY3009806
- Drug: Cyclophosphamide
- Drug: Vinorelbine
- Drug: Gemcitabine — also filed as LY188011
- Drug: Docetaxel
- Drug: Abemaciclib — also filed as LY2835219
- Drug: Irinotecan
- Drug: Temozolomide
Primary outcome
what the primary-completion date above is the date OFNumber of Participants Allocated to Each ISA
measured Baseline up to Week 4
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2019-09-26 · 618 KB · Prot_000.pdf
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed